Search

Your search keyword '"Cheeseman, Sue"' showing total 22 results
Start Over Author "Cheeseman, Sue"
22 results on '"Cheeseman, Sue"'

1. Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records

Author

Cottu, Paul, Cheeseman, Sue, Hall, Peter, Wöckel, Achim, Scholz, Christian W., Bria, Emilio, Orlandi, Armando, Ribelles, Nuria, Vallet, Mahéva, Niklas, Nicolas, Hogg, Catherine, Aggarwal, Shivani, Moreira, Joana, Lucerna, Markus, Collin, Simon M., Logue, Amanda, and Long, Gráinne H.

Published
2024
Full Text
View/download PDF

3. Reviews

Author

Cheeseman, Sue, Shennan, Jennifer, and Simon, Dagmar

Published
2005

7. Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital

Author

Seesaghur, Anouchka, primary, Egger, Peter, additional, Warden, Joshua, additional, Abbasi, Ali, additional, Levick, Bethany, additional, Riaz, Majid, additional, McMahon, Peter, additional, Thompson, Matthew, additional, and Cheeseman, Sue, additional

Published
2023
Full Text
View/download PDF

8. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes

Author

Cheeseman, Sue, primary, Levick, Bethany, additional, Sopwith, Will, additional, Fenton, Hayley, additional, Nam, Eun Ji, additional, Kim, DongKyu, additional, Lim, Subin, additional, Martin, Elodie, additional, Frenel, Jean-Sébastien, additional, Bocquet, François, additional, Kubelac, Paul, additional, Achimas-Cadariu, Patriciu, additional, Vlad, Catalin, additional, Chevrier, Marion, additional, Rouzier, Roman, additional, Carton, Matthieu, additional, Savva-Bordalo, Joana, additional, Magalhães, Marta, additional, Borges, Marina, additional, Wolf, Andrea, additional, Becker, Sven, additional, Niklas, Nicolas, additional, Guergova-Kuras, Mariana, additional, and Hall, Geoff, additional

Published
2023
Full Text
View/download PDF

9. Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative

Author

Snee, Michael, primary, Cheeseman, Sue, additional, Thompson, Matthew, additional, Riaz, Majid, additional, Sopwith, Will, additional, Lacoin, Laure, additional, Chaib, Carlos, additional, Daumont, Melinda J, additional, Penrod, John R, additional, and Hall, Geoff, additional

Published
2021
Full Text
View/download PDF

10. An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.

Author

Hall, Geoff, primary, Cheeseman, Sue, additional, Levick, Bethany, additional, Nam, Eun Ji, additional, Lim, Subin, additional, Classe, Jean-Marc, additional, Martin, Elodie, additional, Kubelac, Paul, additional, Achimaș-Cadariu, Patriciu, additional, Savva-Bordalo, Joana, additional, Borges, Marina, additional, Becker, Sven, additional, Shaid, Shabnam, additional, Niklas, Nicolas, additional, and Guergova-Kuras, Mariana, additional

Published
2021
Full Text
View/download PDF

11. OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling—The use of a common data model and shared analytical methods.

Author

Levick, Bethany, primary, Cheeseman, Sue, additional, Nam, Eun Ji, additional, Doh, Haewon, additional, Lim, Subin, additional, Kim, DongKyu, additional, Bocquet, Francois, additional, Martin, Elodie, additional, Kubelac, Paul, additional, Achimaș-Cadariu, Patriciu, additional, Calisto, Rita, additional, Magalhães, Marta, additional, Becker, Sven, additional, Wolf, Andrea, additional, Niklas, Nicolas, additional, Guergova-Kuras, Mariana, additional, and Hall, Geoff, additional

Published
2021
Full Text
View/download PDF

12. Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative

Author

Snee, Michael, primary, Cheeseman, Sue, additional, Thompson, Matthew, additional, Riaz, Majid, additional, Sopwith, Will, additional, Lacoin, Laure, additional, Chaib, Carlos, additional, J Daumont, Melinda, additional, Penrod, John R, additional, O’Donnell, John C, additional, and Hall, Geoff, additional

Published
2021
Full Text
View/download PDF

13. MOESM2 of Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

Author

Twelves, Chris, Cheeseman, Sue, Sopwith, Will, Thompson, Matthew, Riaz, Majid, Ahat-Donker, Necibe, Myland, Melissa, Lee, Adam, Przybysz, Raymond, Turner, Stuart, Hall, Geoff, and Perren, Tim

Abstract

Additional file 2. The three most common sequence of regimens received by patients (n = 185) in each major treatment sequence category, showing the total number of patients in each sequence category and the proportion of all treated patients (small number masking in operation).

Published
2020
Full Text
View/download PDF

14. 379 Real world retrospective study of patients with epithelial ovarian cancer: an international comparison

Author

Cheeseman, Sue, primary, Levick, Bethany, additional, Nam, Eunji, additional, Lim, Subin, additional, Rouzier, Roman, additional, Bonneau, Claire, additional, Kubelac, Milan Paul, additional, Achimas-Cadariu, Patriciu A, additional, Classe, Jean Marc, additional, Bocquet, Francois, additional, Becker, Sven, additional, Guergova-Kuras, Mariana, additional, and Hall, Geoff, additional

Published
2020
Full Text
View/download PDF

15. Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre

Author

Cheeseman, Sue, primary, Thompson, Matthew, additional, Sopwith, Will, additional, Godden, Paul, additional, Seshagiri, Divyagiri, additional, Adedokun, Lola, additional, Zucker, Kieran, additional, Jain, Sunjay, additional, Kotwal, Sanjeev, additional, Prescott, Stephen, additional, Henry, Ann, additional, Joseph, Joji, additional, Chilka, Sameer, additional, Roulson, Jo-An, additional, Weston, Michael, additional, Burbidge, Simon, additional, Brown, Simon, additional, Jagdev, Satinder, additional, Ralph, Christy, additional, Hall, Geoff, additional, and Vasudev, Naveen S., additional

Published
2020
Full Text
View/download PDF

16. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P, Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M, Palmer, Daniel H, Campbell, Fiona, Valle, Juan W, Faluyi, Olusola, O'Reilly, Derek A, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J, Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M, Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W, Neoptolemos, John P, Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, and Canc, European Study Grp Pancreatic

Subjects
medicine.medical_specialty, Chemotherapy, Randomization, business.industry, medicine.medical_treatment, 030230 surgery, medicine.disease, Gastroenterology, Gemcitabine, law.invention, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Pancreatic cancer, medicine, Carcinoma, Surgery, Prospective cohort study, business, medicine.drug
Abstract

Importance The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures Overall survival, recurrence, and sites of recurrence. Results Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98;P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45;P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09;P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 andP = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98;P = .03). Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection. Trial Registration ClinicalTrials.gov identifier:NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434.

Published
2019

17. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, and Millat, Bertrand

Abstract

Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence. Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P=.03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P=.04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P=.27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32

Published
2019
Full Text
View/download PDF

18. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

Author

Twelves, Chris, primary, Cheeseman, Sue, additional, Sopwith, Will, additional, Thompson, Matthew, additional, Riaz, Majid, additional, Ahat-Donker, Necibe, additional, Myland, Melissa, additional, Lee, Adam, additional, Przybysz, Raymond, additional, Turner, Stuart, additional, Hall, Geoff, additional, and Perren, Tim, additional

Published
2019
Full Text
View/download PDF

19. Erratum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Author

Dalgleish, Angus G, primary, Stebbing, Justin, additional, Adamson, Douglas J A, additional, Arif, Seema Safia, additional, Bidoli, Paolo, additional, Chang, David, additional, Cheeseman, Sue, additional, Diaz-Beveridge, Robert, additional, Fernandez-Martos, Carlos, additional, Glynne-Jones, Rob, additional, Granetto, Cristina, additional, Massuti, Bartomeu, additional, McAdam, Karen, additional, McDermott, Raymond, additional, Martín, Andrés J Muñoz, additional, Papamichael, Demetris, additional, Pazo-Cid, Roberto, additional, Vieitez, Jose M, additional, Zaniboni, Alberto, additional, Carroll, Kevin J, additional, Wagle, Shama, additional, Gaya, Andrew, additional, and Mudan, Satvinder S, additional

Published
2016
Full Text
View/download PDF

20. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Author

Dalgleish, Angus G, primary, Stebbing, Justin, additional, Adamson, Douglas JA, additional, Arif, Seema Safia, additional, Bidoli, Paolo, additional, Chang, David, additional, Cheeseman, Sue, additional, Diaz-Beveridge, Robert, additional, Fernandez-Martos, Carlos, additional, Glynne-Jones, Rob, additional, Granetto, Cristina, additional, Massuti, Bartomeu, additional, McAdam, Karen, additional, McDermott, Raymond, additional, Martín, Andrés J Muñoz, additional, Papamichael, Demetris, additional, Pazo-Cid, Roberto, additional, Vieitez, Jose M, additional, Zaniboni, Alberto, additional, Carroll, Kevin J, additional, Wagle, Shama, additional, Gaya, Andrew, additional, and Mudan, Satvinder S, additional

Published
2016
Full Text
View/download PDF

21. Three, two, or one drug chemotherapy for frail or elderly patients with advanced gastroesophageal cancer (321GO): A feasibility study.

Author

Hall, Peter S., primary, Lord, Simon, additional, Collinson, Michelle, additional, Marshall, Helen, additional, Jones, Marc, additional, Olivier, Catherine, additional, Howard, Helen, additional, Seligman, Jenny, additional, Swinson, Daniel, additional, Roy, Rajarshi, additional, Dent, Jo, additional, Cheeseman, Sue, additional, Last, Kim William, additional, and Seymour, Matthew T., additional

Published
2012
Full Text
View/download PDF

22. Algorithms to identify radiotherapy intent in unresected non-metastatic non-small-cell lung cancer: an I-O Optimise analysis.

Author

Ralphs E, Rault C, Calleja A, Daumont MJ, Penrod JR, Thompson M, Cheeseman S, and Soares M

Subjects
Humans, Male, Female, Aged, Middle Aged, Radiotherapy Dosage, Neoplasm Staging, Radiotherapy Planning, Computer-Assisted methods, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms radiotherapy, Lung Neoplasms pathology, Algorithms
Abstract

This study aimed to develop and evaluate the performance of algorithms for identifying radiotherapy (RT) treatment intent in real-world data from patients with non-metastatic non-small-cell lung cancer (NSCLC). Using data from IPO-Porto hospital (Portugal) and the REAL-Oncology database (England), three algorithms were developed based on available RT information (#1: RT duration, #2: RT duration and type, #3: RT dose) and tested versus reference datasets. Study results showed that all three algorithms had good overall accuracy (91-100%) for patients receiving RT plus systemic anticancer therapy (SACT) and algorithms #2 and #3 also had good accuracy (>99%) for patients receiving RT alone. These algorithms could help classify treatment intent in patients with NSCLC receiving RT with or without SACT in real-world settings where intent information is missing/incomplete.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results